羚邦集團(02230.HK):正研究未來舉辦線下動漫演唱會
羚邦集團(02230.HK)行政總裁趙小燕表示,集團早前定下的5年計劃已陸續實現,逐步優化生態鏈,並正規劃下一個5年大計,未來會繼續推動IP品牌面向全球。
她指,目前集團簽了共7名藝術家的IP品牌,並獨家擁有,期望未來能繼續增加;又指截至5月中,其動漫平台的YouTube擁有超過322萬名訂閱使用者及錄得逾6.1億瀏覽量。
她透露,計及港澳地區,目前Slam Dunk已破4,300萬以上票房,認為是超過預期;她表示,集團研究未來舉辦以動漫為主的線下演唱會,旨滿足粉絲需求,希望能利好集團未來增長。(ca/k)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.